Inari Medical Inc
NASDAQ:NARI

Watchlist Manager
Inari Medical Inc Logo
Inari Medical Inc
NASDAQ:NARI
Watchlist
Price: 53.53 USD -0.22%
Market Cap: 3.1B USD
Have any thoughts about
Inari Medical Inc?
Write Note

Inari Medical Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Inari Medical Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Inari Medical Inc
NASDAQ:NARI
Additional Paid In Capital
$504.5m
CAGR 3-Years
30%
CAGR 5-Years
225%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Additional Paid In Capital
$21B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
2%
Stryker Corp
NYSE:SYK
Additional Paid In Capital
$2.4B
CAGR 3-Years
8%
CAGR 5-Years
8%
CAGR 10-Years
7%
Abbott Laboratories
NYSE:ABT
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Intuitive Surgical Inc
NASDAQ:ISRG
Additional Paid In Capital
$9.4B
CAGR 3-Years
10%
CAGR 5-Years
11%
CAGR 10-Years
13%
No Stocks Found

Inari Medical Inc
Glance View

Market Cap
3.1B USD
Industry
Health Care

Inari Medical Inc., nestled in the heart of Irvine, California, embarked on a mission to revolutionize the treatment for venous diseases with a sense of urgency and ingenuity. Founded in 2011, this medical device company has become a beacon of innovation in the healthcare sector, relentlessly focused on addressing the unmet needs in the treatment of venous thromboembolism (VTE) conditions, such as deep vein thrombosis (DVT) and pulmonary embolism (PE). These life-threatening conditions impact millions globally, presenting a critical challenge that Inari aims to tackle head-on. Their pioneering spirit is showcased in their flagship devices—the FlowTriever and ClotTriever—designed to remove large clots with less risk compared to traditional, invasive surgical methods. By providing minimally invasive mechanical thrombectomy devices, Inari Medical has streamlined treatments to improve patient outcomes, ultimately reducing the burden on healthcare systems. Revenue streams at Inari are intrinsically tied to their innovative products, which are integral in modern therapeutic strategies for clot removal. The commercial success of FlowTriever and ClotTriever is driven by their effectiveness and safety profile, appealing to hospitals and medical professionals looking for advanced solutions to treat VTE. Inari's business model thrives on the sales and adoption of these devices, supported by robust clinical evidence that underpins their efficacy. With a blend of aggressive research and development, education programs for physicians, and a strategic global market expansion, Inari Medical is poised to continue growing in the med-tech sector. Their commitment to addressing large medical needs with cutting-edge solutions not only defines their financial blueprint but also underscores their dedication to transforming patient care across the globe.

NARI Intrinsic Value
36.37 USD
Overvaluation 32%
Intrinsic Value
Price

See Also

What is Inari Medical Inc's Additional Paid In Capital?
Additional Paid In Capital
504.5m USD

Based on the financial report for Dec 31, 2023, Inari Medical Inc's Additional Paid In Capital amounts to 504.5m USD.

What is Inari Medical Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 5Y
225%

Over the last year, the Additional Paid In Capital growth was 9%. The average annual Additional Paid In Capital growth rates for Inari Medical Inc have been 30% over the past three years , 225% over the past five years .

Back to Top